Department of Dermato-Allergology, National Allergy Research Centre, Copenhagen University Hospital Gentofte, University of Copenhagen, DK-2900 Hellerup, Denmark.
Contact Dermatitis. 2011 Aug;65(2):76-80. doi: 10.1111/j.1600-0536.2010.01858.x. Epub 2011 Jan 13.
BACKGROUND. Allergens included in the European baseline series should result in positive patch test reactions in at least 1% of a patch test population. Inclusion of local anaesthetics other than benzocaine in the baseline series has previously been debated.
To investigate temporal trends of benzocaine and lidocaine allergy in dermatitis patients who underwent routine patch testing in a tertiary referral patch test centre, and to clarify and discuss whether lidocaine and benzocaine should be included in routine series.
Dermatitis patients who underwent routine patch testing with benzocaine as a part of the European baseline series between 1985 and 2010 (n = 19 347) and dermatitis patients who underwent routine patch testing with lidocaine between 1994 and 2001 (n = 6265) and between 2007 and 2009 (n = 1360) were included.
The overall prevalences of contact allergy were 0.5% (benzocaine), 0.3% (lidocaine for the period 1994-2001), and 0.14% (lidocaine for the period 2007-2009). Current relevance was observed in 10% of those with benzocaine allergy and in 5% of those with lidocaine allergy.
Benzocaine and lidocaine allergy is infrequent in Danish dermatitis patients. Lidocaine should only be used for aimed testing, and benzocaine should be removed from the baseline series used in Denmark.
调查在一家三级转诊斑贴试验中心进行常规斑贴试验的皮炎患者中，苯佐卡因和利多卡因过敏的时间趋势，并阐明和讨论是否应将利多卡因和苯佐卡因纳入常规系列。
纳入 1985 年至 2010 年间（n=19347）常规斑贴试验中使用苯佐卡因作为欧洲基线系列一部分的皮炎患者，以及 1994 年至 2001 年间（n=6265）和 2007 年至 2009 年间（n=1360）常规斑贴试验中使用利多卡因的皮炎患者。
接触过敏的总体患病率为 0.5%（苯佐卡因）、0.3%（1994-2001 年期间的利多卡因）和 0.14%（2007-2009 年期间的利多卡因）。苯佐卡因过敏者中有 10%和利多卡因过敏者中有 5%存在当前相关性。
丹麦皮炎患者中苯佐卡因和利多卡因过敏少见。利多卡因仅应用于有针对性的测试，而苯佐卡因应从丹麦使用的基线系列中去除。
